SCHEMBL12919982

SCHEMBL12919982

CC(C)c1ccc(-c2cncc3ccccc23)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 1/20 0.68
CYP11B1 P15538 7/20 0.52
CYP11B2 P19099 7/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2B6 P20813 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CCNC P24863 6/20 0.49
CDK8 P49336 6/20 0.49
TLR9 Q9NR96 1/20 0.47
KDR P35968 1/20 0.46
WNT1 P04628 1/20 0.44
DYRK1A Q13627 1/20 0.44
FLT3 P36888 1/20 0.44
MYLK Q15746 1/20 0.44
AURKB Q96GD4 1/20 0.44
CILK1 Q9UPZ9 1/20 0.44
CDK11A Q9UQ88 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12386960 0.81 PRKCZ (0.69) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL526801 0.81 PRKCZ (1.00) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL20095043 0.81 KDR (0.56) PRKCZCYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL12074301 0.80 PRKCZ (0.73) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL29501875 0.80 PRKCZ (0.72) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL6243938 0.80 PRKCZ (0.72) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL23555363 0.79 PRKCZ (0.67) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL10806364 0.78 PRKCZ (0.69) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL12074902 0.77 PRKCZ (0.69) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9
SCHEMBL38660559 0.77 PRKCZ (0.69) PRKCZCYP11B1CYP11B2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 PRKCZ 4475/4885CYP11B1 886/4885CYP11B2 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.